Last update: June 15, 2019


Very Low Risk for breastfeeding

Safe. Compatible.
Not risky for breastfeeding or infant.

Antiprotozoal and antibacterial (anerobic bacteria). Indicated in urogenital trichomoniasis, nonspecific vaginitis, giardiasis, intestinal and hepatic amebiasis, acute ulcerative gingivitis and prophylaxis of postoperative infections by anaerobic bacteria.
Administered orally or intravenously in a single or daily dose for 3 to 6 days according to pathology.

It is excreted into breast milk in clinically non-significant amount (Evaldson 1985, Männistö 1983, Wood 1982) which is much lower than the dose that is prescribed to infants.

This medication is authorized for use in infants older than 1 month of age.

Some authors recommend waiting 72 hours after the last dose before restarting breastfeeding (CDC 2010, Evaldson 1985). Meanwhile, express and discard breastmilk regularly.

Be aware of false negative results of bacterial cultures obtained from febrile infants whose mothers are on antibiotics, as well as the possibility of gastroenteritis due to altered intestinal flora (Ito 1993).

When topically used with creams and vaginal ovules, absorption into serum is scanty, hence, excretion into breast milk is believed lower than that attained by systemic administration.


Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Tinidazole in other languages or writings:


Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 247 daltons
Protein Binding 12 %
VD 0,8 l/Kg
Tmax 2 hours
T1/2 12 - 14 hours
M/P ratio 1,3 -
Theoretical Dose 0,87 - 1,91 mg/Kg/d
Relative Dose 2,6 - 5,7 %
Relat.Ped.Dose 1,2 - 3,8 %


  1. CDC - Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010 Abstract Full text (link to original source) Full text (in our servers)
  2. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  3. Roe FJ. Safety of nitroimidazoles. Scand J Infect Dis Suppl. 1985 Abstract
  4. Evaldson GR, Lindgren S, Nord CE, Rane AT. Tinidazole milk excretion and pharmacokinetics in lactating women. Br J Clin Pharmacol. 1985 Abstract Full text (link to original source) Full text (in our servers)
  5. Männistö PT, Karhunen M, Koskela O, Suikkari AM, Mattila J, Haataja H. Concentrations of tinidazole in breast milk. Acta Pharmacol Toxicol (Copenh). 1983 Abstract
  6. Wood BA, Faulkner JK, Monro AM. The pharmacokinetics, metabolism and tissue distribution of tinidazole. J Antimicrob Chemother. 1982 Abstract
  7. Chaikin P, Alton KB, Sampson C, Weintraub HS. Pharmacokinetics of tinidazole in male and female subjects. J Clin Pharmacol. 1982 Abstract
  8. Andersson KE. Pharmacokinetics of nitroimidazoles. Spectrum of adverse reactions. Scand J Infect Dis Suppl. 1981 Abstract
  9. Wood BA, Monro AM. Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses. Br J Vener Dis. 1975 Abstract Full text (link to original source) Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by Instituto de Salud Infantil, Grecia-Institute of Child's Health in Greece

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM